Haemophilia ATMP Treatment Hub for the Midlands Region

This is a contract result notice, not an open opportunity. Details from the official award data.

Following the publication of a provider selection process in March 2023, the Lot to cover the Midlands region was unsuccessfully awarded.

The key objectives of this Procurement are to commission a Haemophilia Advanced Therapy Medicinal Product (ATMP) treatment hub to serve the population of the Midlands NHS region in England for patients with haemophilia types A and B and to ensure that: • the provider of the Haemophilia ATMP treatment hub in the Midlands NHS region has the correct qualifications and governance arrangements in place to provide these treatments for the NHS, and • the Commissioner is offering services that are safe and of a high standard whilst fulfilling the Commissioner's public duty to provide services that are cost-effective.

The National Institute for Health and Care Excellence (NICE) will be assessing a number of ATMPs for haemophilia A and B (see Appendix A).

To meet the requirements of the expected NICE guidance, NHS England published a provider selection process to commissioning Haemophilia ATMP treatment hubs for patients with haemophilia types A and B in summer 2023.

Due to the Midlands Lot not being successfully awarded, NHS England is seeking to commission an adult Comprehensive Care Centre (CCC) in the Midlands to become a 'haemophilia ATMP treatment hub'.

This hub will deliver the haemophilia gene therapy ATMPs approved by NICE with a contract duration of 8 years with the option to extend for up to a further 18 months to co-terminate with the contracts from the provider selection process that were successfully awarded.

Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has made its recommendations to commence commissioning activity.

To do so would risk the NHS not being ready to provide access according to statutory requirements on NICE approved treatments.

Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that the product does not receive a positive NICE recommendation.

Bidders are responsible for their own costs incurred throughout each stage of the procurement and contract award process.

NHS England is not responsible for costs beyond treatment and service set up.

CSL Behring is the company responsible for the expected first ATMP to market in England, known as etranacogene dezaparvovec (Hemgenix®).

Providers will need to comply with the company's onboarding requirements for the product.